Page last updated: 2024-11-02

pamidronate and Bone Diseases, Metabolic

pamidronate has been researched along with Bone Diseases, Metabolic in 47 studies

Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to test the efficacy of low doses of pamidronate in increasing bone mineral density (BMD) in non-ambulatory children and adolescents with cerebral palsy (CP)."9.12Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. ( Bruzoni, M; Coughlin, S; Heldt, K; Kreikemeier, R; Lerner, G; Plotkin, H, 2006)
"Intravenous pamidronate increases axial BMD in adults with cystic fibrosis, but the high incidence of bone pain associated with this treatment might limit its use."9.09Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. ( Adams, JE; Haworth, CS; Horrocks, AW; Mawer, EB; Selby, PL; Webb, AK, 2001)
"To investigate if intravenous pamidronate improves bone density in a cohort of patients with chronic neurological conditions and low bone density, in whom fractures and bone pain are impacting on care."7.76Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. ( Davis, E; Howe, W; Valentine, J, 2010)
"All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI."6.77Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012)
"The aim of this study was to test the efficacy of low doses of pamidronate in increasing bone mineral density (BMD) in non-ambulatory children and adolescents with cerebral palsy (CP)."5.12Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. ( Bruzoni, M; Coughlin, S; Heldt, K; Kreikemeier, R; Lerner, G; Plotkin, H, 2006)
"To evaluate in a double-blind, placebo-controlled clinical trial the safety and efficacy of intravenous pamidronate to treat osteopenia in nonambulatory children with cerebral palsy."5.10Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. ( Bachrach, SJ; Harcke, HT; Henderson, RC; Kecskemethy, HH; Lark, RK; Miller, F, 2002)
"Intravenous pamidronate increases axial BMD in adults with cystic fibrosis, but the high incidence of bone pain associated with this treatment might limit its use."5.09Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. ( Adams, JE; Haworth, CS; Horrocks, AW; Mawer, EB; Selby, PL; Webb, AK, 2001)
"To investigate if intravenous pamidronate improves bone density in a cohort of patients with chronic neurological conditions and low bone density, in whom fractures and bone pain are impacting on care."3.76Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. ( Davis, E; Howe, W; Valentine, J, 2010)
"In recent years, bisphosphonates, primarily intravenous (iv) pamidronate, have become very widely used in children with severe osteogenesis imperfecta (OI)."3.73Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children. ( Henderson, R, 2006)
" Bone densitometry is particularly effective for early detection of patients at risk for fracture and is of practical interest since patients with osteoporosis can now be treated with Pamidronate."3.71[Bone evaluation in ten adults with cutaneous mastocytosis]. ( Armingaud, P; Benhamou, CL; Estève, E; Kerdraon, R; Lespessailles, E; Petavy-Catala, C; Zerkak, D, 2002)
"The successful use of pamidronate, a bisphosphonate, for the treatment of hypercalcemia and/or osteopenia is reported in three children with renal failure or following renal transplant."3.70The use of pamidronate in three children with renal disease. ( Rodd, C; Sellers, E; Sharma, A, 1998)
"All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI."2.77Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012)
"Pamidronate was comparable to alendronate in prevention of early bone loss after kidney transplantation."2.76Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation. ( Alasti, M; Beladi Mousavi, SS; Ghorbani, A; Omidvar, B; Shahbazian, H; Shariat Nabavi, SJ, 2011)
"In contrast, inhibition of bone resorption by pamidronate could preserve bone mineral and reduce the risk of renal stone formation during prolonged bed rest."2.71Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. ( Felsenberg, D; Fukunaga, M; Kohri, K; Matsumoto, T; Mizuno, K; Nakamura, T; Ohshima, H; Rittweger, J; Sekiguchi, C; Watanabe, Y, 2004)
"Very rapid bone loss, osteopenia and skeletal morbidity after renal transplantation have been well documented and found to occur in a sex dependent fashion."2.69Pamidronate therapy as prevention of bone loss following renal transplantation. ( Almond, MK; Ball, E; Cunningham, J; Evans, K; Fan, SL, 2000)
"Hypercalcemia has been described as a possible complication of many pediatric malignancies."2.45Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature. ( Ahmed, I; Cushing, B; Qayed, M; Rajpurkar, M; Valentini, RP, 2009)
" Pre-treatment with the bisphosphonate pamidronate started at 4 weeks of age over a period of 2 weeks or 6 weeks (cumulative dose 8 mg/kg for both) to assess the effectiveness of the two dosing regimens in ameliorating glucocorticoid-induced bone loss."1.51Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids. ( Chen, J; Grynpas, MD; Mitchell, J; Yoon, SH, 2019)
"The inhibition of bone resorption by pamidronate in osteopenic mice alleviates the histological OA score with a reduction in the expression of aggrecanases."1.38Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. ( Ah Kioon, MD; Cohen-Solal, ME; de Vernejoul, MC; Funck-Brentano, T; Hannouche, D; Hay, E; Lin, H; Lioté, F; Nizard, R; Orcel, P; Schiltz, C, 2012)
" Adverse events were measured by collecting calcium levels before and after infusions."1.38Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings. ( DeHaai, K; Kreikemeier, RM; Lutz, RE; Rush, ET, 2012)
"pamidronate was given for 6 months."1.31[Fibrous dysplasia: differential diagnosis from Paget's disease]. ( Heilmann, P; Kasperk, Ch; Nawroth, P; Schulz, A; Wagner, P, 2002)
"Pamidronate treatment seemed to increase trabecular bone density, although it was not effective in maintaining the AWcc of the operated extremity."1.31Pamidronate increases trabecular bone mineral density in immobilization osteopenia in male rats. ( Alhava, E; Arnala, I; Huuskonen, J; Olkkonen, H, 2001)
"In a model of preestablished osteopenia, caused by estrogen deprivation, OLPA stopped the progression of the bone mass loss (0."1.30[Experimental effects of olpadronate and pamidronate on bone mass]. ( Mondelo, N; Montuori, E; Parma, MD; Peluffo, VA; Piccinni, E; Zanchetta, JR, 1997)
"6 mg/kg of MDL 103,323 did not further increase BMD or bone strength, indicating a bell-shaped dose-response curve."1.30The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats. ( Ammann, P; Bonjour, JP; Bourrin, S; Brunner, F; Meyer, JM; Rizzoli, R, 1999)
"Immobilization in this model induces osteopenia and increases turnover in cancellous bone."1.29The effect of pamidronate in a new model of immobilization in the dog. ( Grynpas, MD; Kasra, M; Pritzker, KP; Renlund, R, 1995)
"No hypocalcemia was detected."1.29[Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients]. ( Castelli, G; Kerzberg, EM; Lloret, AP; Roldan, EJ, 1996)

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.13)18.7374
1990's11 (23.40)18.2507
2000's21 (44.68)29.6817
2010's14 (29.79)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jain, N1
Reilly, RF1
Spirlandeli, AL1
Dick-de-Paula, I1
Zamarioli, A1
Jorgetti, V1
Ramalho, LNZ1
Nogueira-Barbosa, MH1
Volpon, JB1
Jordão, AA1
Cunha, FQ1
Fukada, SY1
de Paula, FJA1
Chen, J1
Yoon, SH1
Grynpas, MD2
Mitchell, J1
Pirbhai, A1
Rajak, SN1
Goold, LA1
Cunneen, TS1
Wilcsek, G1
Martin, P1
Leibovitch, I1
Selva, D1
Veszelyné Kotán, E1
Mészaros, Á1
Qayed, M1
Ahmed, I1
Valentini, RP1
Cushing, B1
Rajpurkar, M1
Dayer, R1
Brennan, TC1
Rizzoli, R2
Ammann, P2
Chatterjee, R2
Bajoria, R2
Howe, W1
Davis, E1
Valentine, J1
Torregrosa, JV1
Fuster, D1
Monegal, A1
Gentil, MA1
Bravo, J1
Guirado, L1
Muxí, A1
Cubero, J1
Arundel, P1
Offiah, A1
Bishop, NJ1
Bartl, R1
Omidvar, B1
Ghorbani, A1
Shahbazian, H1
Beladi Mousavi, SS1
Shariat Nabavi, SJ1
Alasti, M1
Funck-Brentano, T1
Lin, H1
Hay, E1
Ah Kioon, MD1
Schiltz, C1
Hannouche, D1
Nizard, R1
Lioté, F1
Orcel, P1
de Vernejoul, MC1
Cohen-Solal, ME1
Rush, ET1
DeHaai, K1
Kreikemeier, RM1
Lutz, RE1
Shah, FT1
Davis, BA1
Byers, M1
Sooranna, D1
Pringle, J1
Porter, JB1
Younes, H1
Farhat, G1
el-Hajj Fuleihan, G1
Barr, RD1
Guo, CY1
Wiernikowski, J1
Webber, C1
Wright, M1
Atkinson, S1
Wagner, P1
Heilmann, P1
Schulz, A1
Nawroth, P1
Kasperk, Ch1
Henderson, RC1
Lark, RK1
Kecskemethy, HH1
Miller, F1
Harcke, HT2
Bachrach, SJ1
Lee, CT1
Huynh, VM1
Lai, LW1
Lien, YH1
Grissom, LE1
Montangero, VE1
Capiglioni, R1
Roldán, EJ2
Watanabe, Y1
Ohshima, H1
Mizuno, K1
Sekiguchi, C1
Fukunaga, M1
Kohri, K1
Rittweger, J1
Felsenberg, D1
Matsumoto, T1
Nakamura, T1
Bin-Abbas, BS1
Al-Ashwal, AA1
Al-Zayed, ZS1
Sakati, NA1
Tokumoto, T1
Tanabe, K1
Toma, H1
Akiba, T1
Lipton, A1
Nasr, SH1
Preddie, DC1
Markowitz, GS1
Appel, GB1
D'Agati, VD1
Henderson, R1
Plotkin, H1
Coughlin, S1
Kreikemeier, R1
Heldt, K1
Bruzoni, M1
Lerner, G1
Cheng, PT1
Chan, C1
Müller, K1
Nimni, ME1
Garnero, P1
Grimaux, M1
Seguin, P1
Delmas, PD1
Abe, T1
Chow, JW1
Lean, JM1
Chambers, TJ1
Ferretti, JL1
Delgado, CJ1
Capozza, RF1
Cointry, G1
Montuori, E2
Roldán, E1
Pérez Lloret, A1
Zanchetta, JR2
Kanis, JA1
Kasra, M1
Renlund, R1
Pritzker, KP1
Kerzberg, EM1
Castelli, G1
Lloret, AP1
Mondelo, N1
Parma, MD1
Peluffo, VA1
Piccinni, E1
Sellers, E1
Sharma, A1
Rodd, C1
Bourrin, S1
Bonjour, JP1
Brunner, F1
Meyer, JM1
Fan, SL1
Almond, MK1
Ball, E1
Evans, K1
Cunningham, J1
Haworth, CS1
Selby, PL1
Adams, JE1
Mawer, EB1
Horrocks, AW1
Webb, AK1
Huuskonen, J1
Arnala, I1
Olkkonen, H1
Alhava, E1
Zeni, S1
Gomez-Acotto, C1
Mautalen, C1
Armingaud, P1
Zerkak, D1
Lespessailles, E1
Petavy-Catala, C1
Kerdraon, R1
Benhamou, CL1
Estève, E1
Tan, PL1
Katz, JM1
Ames, R1
Caughey, DE1
Gray, HD1
Ibbertson, HK1
Watson, JD1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631]Phase 280 participants (Actual)Interventional2015-02-28Completed
Simulation of a Mission Aboard the International Space Station by a Long Duration Anti-Orthostatic Bed Confinement at - 6° (90 Days) on Healthy Subjects:1/Perfecting of Preventive Methods (Muscular Exercise and Biphosphonates) and Evaluation of the Effect[NCT00311571]Phase 128 participants Interventional2001-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

7 reviews available for pamidronate and Bone Diseases, Metabolic

ArticleYear
Hungry bone syndrome.
    Current opinion in nephrology and hypertension, 2017, Volume: 26, Issue:4

    Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Diphosphonates; Hum

2017
Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review.
    Orbit (Amsterdam, Netherlands), 2015, Volume: 34, Issue:6

    Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Di

2015
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
    Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1

    Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A

2016
Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases, Met

2009
[Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines].
    Clinical calcium, 2004, Volume: 14, Issue:5

    Topics: Bone Density; Bone Diseases, Metabolic; Calcitonin; Chronic Disease; Diphosphonates; Epoxy Compounds

2004
New therapeutic agents for the treatment of bone diseases.
    Expert opinion on biological therapy, 2005, Volume: 5, Issue:6

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bo

2005
Bone and cancer: pathophysiology and treatment of metastases.
    Bone, 1995, Volume: 17, Issue:2 Suppl

    Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms

1995

Trials

9 trials available for pamidronate and Bone Diseases, Metabolic

ArticleYear
Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment.
    Hemoglobin, 2009, Volume: 33 Suppl 1

    Topics: Absorptiometry, Photon; Anti-Inflammatory Agents; Bone Diseases, Metabolic; Diphosphonates; Female;

2009
Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:1

    Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeli

2011
Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
    Iranian journal of kidney diseases, 2011, Volume: 5, Issue:6

    Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents; Bone Den

2011
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome.
    British journal of haematology, 2012, Volume: 159, Issue:4

    Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabo

2012
Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial.
    The Journal of pediatrics, 2002, Volume: 141, Issue:5

    Topics: Adolescent; Bone Diseases, Metabolic; Cerebral Palsy; Child; Diphosphonates; Double-Blind Method; Fe

2002
Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:11

    Topics: Adult; Alkaline Phosphatase; Bed Rest; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Meta

2004
Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.
    Developmental medicine and child neurology, 2006, Volume: 48, Issue:9

    Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cerebral Palsy

2006
Pamidronate therapy as prevention of bone loss following renal transplantation.
    Kidney international, 2000, Volume: 57, Issue:2

    Topics: Absorptiometry, Photon; Adult; Aged; Alkaline Phosphatase; Aluminum; Anti-Inflammatory Agents; Bone

2000
Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis.
    Thorax, 2001, Volume: 56, Issue:4

    Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Calcium; Cystic

2001

Other Studies

31 other studies available for pamidronate and Bone Diseases, Metabolic

ArticleYear
Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment.
    Clinics (Sao Paulo, Brazil), 2017, Volume: 72, Issue:4

    Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling

2017
Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids.
    Calcified tissue international, 2019, Volume: 104, Issue:2

    Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Diseases, Metabolic; Cancellous Bone; Cortica

2019
PTH improves titanium implant fixation more than pamidronate or renutrition in osteopenic rats chronically fed a low protein diet.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:6

    Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Bone Density Conservation Agents;

2010
Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions.
    Developmental neurorehabilitation, 2010, Volume: 13, Issue:1

    Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Child; Diphosp

2010
Evolution of the radiographic appearance of the metaphyses over the first year of life in type V osteogenesis imperfecta: clues to pathogenesis.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2011, Volume: 26, Issue:4

    Topics: Arm Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cranial Fontanelles; Diphosph

2011
[Inflammation of the jaws during treatment with bisphosphonates].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:41

    Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseas

2011
Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism.
    PloS one, 2012, Volume: 7, Issue:3

    Topics: ADAM Proteins; ADAMTS5 Protein; Animals; Bone and Bones; Bone Diseases, Metabolic; Bone Resorption;

2012
Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.
    Journal of pediatric endocrinology & metabolism : JPEM, 2012, Volume: 25, Issue:5-6

    Topics: Adolescent; Ambulatory Care; Bone Density Conservation Agents; Bone Diseases, Metabolic; Child; Cost

2012
Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass.
    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry, 2002,Summer, Volume: 5, Issue:2

    Topics: Adult; Aged; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Injections, Int

2002
Osteopenia in children with acute lymphoblastic leukemia: a pilot study of amelioration with Pamidronate.
    Medical and pediatric oncology, 2002, Volume: 39, Issue:1

    Topics: Adolescent; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr

2002
[Fibrous dysplasia: differential diagnosis from Paget's disease].
    Deutsche medizinische Wochenschrift (1946), 2002, Oct-25, Volume: 127, Issue:43

    Topics: Absorptiometry, Photon; Adult; Anti-Inflammatory Agents; Biopsy; Bone Diseases, Metabolic; Diagnosis

2002
Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout and wild-type mice.
    Kidney international, 2002, Volume: 62, Issue:6

    Topics: Animals; Anti-Inflammatory Agents; Bone Diseases, Metabolic; Calbindin 1; Calbindins; Calcium; Calci

2002
Radiographic features of bisphosphonate therapy in pediatric patients.
    Pediatric radiology, 2003, Volume: 33, Issue:4

    Topics: Adolescent; Bone and Bones; Bone Density; Bone Development; Bone Diseases, Metabolic; Cerebral Palsy

2003
Mandible and maxilla bone mineral density and threshold analysis studies by pQCT in two edentulous women receiving pamidronate.
    Cranio : the journal of craniomandibular practice, 2003, Volume: 21, Issue:2

    Topics: Bone Demineralization, Pathologic; Bone Density; Bone Diseases, Metabolic; Bone Marrow; Calcificatio

2003
Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta.
    Saudi medical journal, 2004, Volume: 25, Issue:11

    Topics: Absorptiometry, Photon; Bone Density; Bone Diseases, Metabolic; Child; Child, Preschool; Diphosphona

2004
Multiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytes.
    Kidney international, 2006, Volume: 69, Issue:3

    Topics: Acute Kidney Injury; Albumins; Bone Density Conservation Agents; Bone Diseases, Metabolic; Creatinin

2006
Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children.
    Developmental medicine and child neurology, 2006, Volume: 48, Issue:9

    Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cerebral Palsy; Child; Chi

2006
Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:1

    Topics: Analysis of Variance; Animals; Bone and Bones; Bone Development; Bone Diseases, Metabolic; Diphospho

1995
Biochemistry of bone induction and dystrophic calcification.
    Clinics in plastic surgery, 1994, Volume: 21, Issue:3

    Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Bone Demineralization Technique; Bone Diseases, Met

1994
Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1994, Volume: 9, Issue:2

    Topics: Adult; Antibodies, Monoclonal; Bone Diseases, Metabolic; Bone Neoplasms; Cell Line; Diphosphonates;

1994
Estrogen does not restore bone lost after ovariectomy in the rat.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1993, Volume: 8, Issue:7

    Topics: Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Diphospho

1993
Protective effects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat femurs.
    Bone and mineral, 1993, Volume: 20, Issue:3

    Topics: Animals; Betamethasone; Biomechanical Phenomena; Bone Diseases, Metabolic; Diphosphonates; Etidronic

1993
The effect of pamidronate in a new model of immobilization in the dog.
    Bone, 1995, Volume: 17, Issue:4 Suppl

    Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Disease Mo

1995
[Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients].
    Medicina, 1996, Volume: 56, Issue:2

    Topics: Administration, Oral; Analysis of Variance; Bone Diseases, Metabolic; Bone Resorption; Calcium, Diet

1996
[Experimental effects of olpadronate and pamidronate on bone mass].
    Medicina, 1997, Volume: 57 Suppl 1

    Topics: Analysis of Variance; Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Diphosphonate

1997
The use of pamidronate in three children with renal disease.
    Pediatric nephrology (Berlin, Germany), 1998, Volume: 12, Issue:9

    Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Child; Diphosphonates;

1998
The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1999, Volume: 10, Issue:5

    Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Bone Diseases, Metabolic; Bone Remodeling; C

1999
Pamidronate increases trabecular bone mineral density in immobilization osteopenia in male rats.
    Annales chirurgiae et gynaecologiae, 2001, Volume: 90, Issue:1

    Topics: Animals; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Femur; Immobilization; Male; Pamidr

2001
Do different aminobisphosphonates have similar preventive effect on experimental thyroid hormone-induced osteopenia in rats?
    Calcified tissue international, 2001, Volume: 69, Issue:5

    Topics: Alendronate; Animals; Body Weight; Bone Diseases, Metabolic; Diphosphonates; Female; Pamidronate; Ra

2001
[Bone evaluation in ten adults with cutaneous mastocytosis].
    Annales de dermatologie et de venereologie, 2002, Volume: 129, Issue:2

    Topics: Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases; Bone Diseases, Metabolic; Bone Marrow

2002
Aminobisphosphonate inhibition of interleukin-1-induced bone resorption in mouse calvariae.
    Arthritis and rheumatism, 1988, Volume: 31, Issue:6

    Topics: Animals; Bone Diseases, Metabolic; Cell Division; Diphosphonates; Interleukin-1; Mice; Pamidronate;

1988